Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial | Zendy

Takayuki Yoshino | Zendy; Eiji Oki | Zendy; Toshihiro Misumi | Zendy; Masahito Kotaka | Zendy; Dai Manaka | Zendy; Tetsuya Eto | Zendy; Junichi Hasegawa | Zendy; Akinori Takagane | Zendy; Masato Nakamura | Zendy; Takeshi Kato | Zendy; Yoshinori Munemoto | Zendy; Fúmitaka Nakamura | Zendy; Hiroyuki Bando | Zendy; Hiroki Taniguchi | Zendy; Yasuhiro Sakamoto | Zendy; Manabu Shiozawa | Zendy; Masayasu Nishi | Zendy; Tetsuya Horiuchi | Zendy; Hisakazu Yamagishi | Zendy; Junichi Sakamoto | Zendy; Tsunekazu Mizushima | Zendy; Atsushi Ohtsu | Zendy; Masaki Mori | Zendy

Open Access

Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial

Author(s) -

Takayuki Yoshino,

Eiji Oki,

Toshihiro Misumi,

Masahito Kotaka,

Dai Manaka,

Tetsuya Eto,

Junichi Hasegawa,

Akinori Takagane,

Masato Nakamura,

Takeshi Kato,

Yoshinori Munemoto,

Fúmitaka Nakamura,

Hiroyuki Bando,

Hiroki Taniguchi,

Yasuhiro Sakamoto,

Manabu Shiozawa,

Masayasu Nishi,

Tetsuya Horiuchi,

Hisakazu Yamagishi,

Junichi Sakamoto,

Tsunekazu Mizushima,

Atsushi Ohtsu,

Masaki Mori

Publication year - 2022

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.21.02628

Subject(s) - medicine , oxaliplatin , folfox , regimen , clinical endpoint , hazard ratio , population , capecitabine , colorectal cancer , surgery , intention to treat analysis , fluorouracil , randomized controlled trial , adjuvant therapy , cancer , confidence interval , environmental health

The phase III ACHIEVE trial conducted in Japan was one of six prospective studies included in the International Duration Evaluation of Adjuvant Therapy collaboration, which explored whether 3 months of adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (CAPOX) therapy would be noninferior to 6 months of treatment in patients with curatively resected stage III colon cancer. We report the final analyses of survival and long-term safety.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research